Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis by Federico Perosa et al.
RESEARCH ARTICLE Open Access
Clinical correlates of a subset of anti-CENP-A
antibodies cross-reacting with FOXE3p53-62 in
systemic sclerosis
Federico Perosa1*, Elvira Favoino1, Giovanna Cuomo2, Liboria Digiglio1, Franco Dammacco3, Marcella Prete3,
Gabriele Valentini2 and Vito Racanelli3
Abstract
Introduction: In a subset of patients with limited cutaneous (lc) systemic sclerosis (SSc), anti-CENP-A antibodies (Ab)
cross-react with a peptide (FOXE3p53-62) that presents striking homology with one of the two immunodominant
epitopes of CENP-A (Ap17-30). We searched for clinical correlates of anti-FOXE3p53-62 Ab by measuring their levels
along with those of Ab to Ap17-30 and to the second immunodominant epitope of CENP-A, namely Ap1-17.
Methods: Serum samples were obtained from 121 patients with SSc, 46 patients with systemic lupus
erythematosus (SLE) and 25 healthy blood donors (HBD). The reactivity of serum IgG to Ap1-17, Ap17-30 and
FOXE3p53-62 was measured by ELISA. The corresponding anti-peptide Ab were affinity-purified from pooled SSc
sera and used to establish standard curves for quantifying these Ab in patients and HBD. Receiver operating
characteristics (ROC) analysis, comparing SSc patients who were positive for anti-CENP Ab (ACA+) to those who
were negative, was used to find cut-off points for dichotomizing the anti-peptide Ab levels into positive and
negative. Clinical records were reviewed to extract demographic data and information about organ involvement
and disease activity.
Results: Of 121 SSc sera, 75 were ACA+; 88.0% of these samples reacted with Ap1-17, 82.6% with Ap17-30 and
53.3% with FOXE3p53-62. Among the 46 ACA- SSc sera, 2.2% reacted with Ap1-17, 4.3% with Ap17-30 and 11%
with FOXE3p53-62. The levels of these Ab were low in ACA-, SLE and HBD groups and not significantly different
among them. When ACA+ SSc patients were divided into subgroups positive or negative for anti-FOXE3p53-62 Ab,
the only variables that were significantly different between groups were the levels of anti-Ap17-30 Ab and disease
activity index (DAI). There was a significant association between negativity for anti-FOXE3p53-62 Ab and active
disease defined as either DAI ≥3 (Fisher exact test, P = 0.045) or less restrictive DAI≥2.5 (P = 0.009).
Conclusions: ACA+-Anti-FOXE3p53-62+Ab identifies a subgroup of patients with lcSSc who are less likely to develop
active disease. In lc SSc patients at presentation, anti-FOXE3p53-62+ can be a marker with prognostic significance.
Keywords: Systemic sclerosis, CENP-A, peptide, FOXE-3, disease activity index
Introduction
Systemic sclerosis (SSc), one of the most disabling con-
nective tissue diseases, causes progressive fibrosis of skin
and internal organs with a heterogeneous spectrum of
clinical manifestations [1,2]. Despite several efforts to
define prognostic markers and develop effective therapies
(reviewed in [3]), its etiology and pathogenesis are largely
unknown. SSc remains the connective tissue disease with
the highest case-specific mortality, with 55% survival at
10 years [4]. Three main pathogenetic events have been
identified as responsible for causing the disease, namely
the development of vasculopathies (the earliest and possi-
bly the primary event), increased collagen synthesis, and
autoimmunity, the latter being characterized at the
humoral level by the presence of anti-nuclear antibodies
(ANA) in up to 95% of patients [2,5-7]. One subset of
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ANA is directed against the family of centromere-asso-
ciated proteins (CENPs). Different types of anti-CENP
antibodies (ACA) have been identified (anti-CENP-A to
-H and anti-CENP-O) [8-12] and those directed to
CENP-A, -B and -C are the most represented in sera of
SSc patients with ACA [1,9,13,14].
Studies on the clinical correlates of anti-CENP-A or -B
antibodies have shown that they are mostly found in sera
of patients with limited SSc (>80% of cases) than diffuse
SSc (18% to 40%) [5,15,16]. In addition, among ACA-
positive (ACA+) SSc patients, the prevalence of pulmon-
ary hypertension (without pulmonary fibrosis) in the
early phase of the disease (10% to 20%) is higher than in
ACA-negative (ACA-) patients (<1%) [15,17]. However,
CENPs (and the corresponding Ab) do not appear to
have any role to explain these clinical correlations. In
order to understand why and how anti-CENP-A Ab are
generated, we recently investigated their fine specificity,
that is, the amino acids recognized by this Ab population,
by focusing on the CENP-A region comprised between
amino acids 17 and 30 (Ap17-30) [18]. This region was
selected because it represents, along with the region
spanning residues 1 to 17 (Ap1-17), the immunodomi-
nant epitope of CENP-A [19]. In that study, we defined
two overlapping anti-CENP-A17-30 Ab motifs and found
that one of them (PTPxxGPxxR) was also present in
human forkhead box protein E3, a transcription factor
encoded by the gene FOXE3. This nuclear protein, which
plays an important role in lens epithelial-to-mesenchymal
transition, had not previously been associated with SSc.
We also observed that the corresponding FOXE3-derived
peptide (FOXE3p53-62) was recognized by serum sam-
ples from only three of eight patients with anti-CENP-
A17-30 Ab [18]. Here, we analyze the occurrence of anti-
FOXE3p53-62 reactivity in sera from a larger sample of
121 patients with SSc (and in patients with systemic
lupus erythematosus, SLE) in order to identify any possi-
ble clinical correlates of anti-FOXE3p53-62 Ab.
Methods
SSc patients
This retrospective study considered data from 121 patients
with SSc who were being treated at the Rheumatology
Units of the Universities of Naples and Bari. The patients
were diagnosed according to the preliminary American
College of Rheumatology criteria for the classification of
the disease [20]. At the presentation, blood was drawn and
the patients underwent an extensive medical evaluation,
which included a patient’s self report (for the recording of
age at diagnosis and at the time of evaluation, sex and eth-
nicity), a routine history report, physical examination, and
laboratory tests, including the assessment of blood cell
counts, erythrocyte sedimentation rate (ESR), total serum
protein (by capillary electrophoresis), C-reactive protein
(CRP), titers of ANA, ACA and anti-topoisomerase-I
(anti-topo-I) Ab, and complement proteins (C3, C4). C3
and C4 levels were considered low when their values were
below the range of normal values. Moreover, tests were
performed for renal (serum creatinine and urea) function.
On the basis of the presence of ACA and anti-topo-I
Ab in their sera, determined on a routine basis using
the anti-CENP-B and anti-Scl70 ELISA kits (Orgentec
Diagnostika GmbH, Germany), the patients were allo-
cated to two groups: (i) ACA+ patients (n = 75); and (ii)
ACA- patients (n = 46). The ACA- group comprised 38
patients with anti-topo-I Ab and 8 without. No ACA+
patient had anti-topo-I Ab. None of the SSc patients
had an overlapping vasculitis.
Disease duration was determined from the onset of
the first Raynaud’s manifestation [15]. The subtype of
SSc, either limited or diffuse, was determined according
to LeRoy et al. [21]. Skin involvement was assessed
using the modified Rodnan skin score (mRss) [22]
whereby the degree of skin thickness is measured in 17
areas and scored from 0 (normal skin) to 3 (severe
thickening), for a total score range of 0 to 51. Bibasilar
fibrosis for interstitial lung disease (ILD) was assessed
with high-resolution computed tomography [23].
Regarding lung function, forced vital capacity (FVC) and
diffusing lung capacity for carbon monoxide (DLCO)
were measured and expressed as the percentage of pre-
dicted values. Systolic pulmonary arterial pressure
(sPAP) was estimated from the tricuspid regurgitant jet
velocity, measured using Doppler echocardiography. Pul-
monary arterial hypertension (PAH) was defined as
sPAP >35 mm Hg [24]. Clinical involvement of organs
and tissues was assessed and scored (from 0 to 4)
according to Medsger et al. [25] in the following
domains: general, peripheral vascular, skin, joint/tendon,
muscle, gastrointestinal tract, lung, heart, and kidney.
Scores for the nine domains were totaled to obtain a
disease severity score [25]. Moreover, the European
Scleroderma Study Group (EScSG) disease activity index
was calculated [26,27]. This index includes ten weighted
items of which three are indicated by patients in refer-
ence to a possible change in conditions over the preced-
ing month, and seven are clinical variables recorded by
the physician. The former include skin deterioration
(score, 0.0 or 2.0), vascular deterioration (0.0 or 0.5),
and deterioration in heart/lung function (0.0 or 2.0); the
latter include mRss>14 (score 0.0 or 1.0), scleredema
(0.0 or 0.5), digital necrosis (0.0 or 0.5), arthritis (0.0 or
0.5), DLCO≤80% of predicted (0.0 or 0.5), ESR (first
hour) >30 mm/h (0.0 or 1.5) and hypocomplementemia
(C3, C4; 0.0 or 1.0). A disease activity index ≥3 was
used to define the activity state of disease [27,28].
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Ethical issues
Approval for the collection of sera from patients and for
the use of their clinical data for research purposes was
obtained from the ethics committees of the University
of Naples and University of Bari. All subjects provided
written informed consent for the clinical samples and
data to be used for research purposes.
Serum samples, reagents and peptides
Serum samples from the 121 SSc patients and from
46 patients with SLE were obtained from the serum
banks at the Departments of Internal Medicine (Univer-
sities of Bari and Naples). In addition, serum from 25
healthy blood donors (HBD) was obtained from the hos-
pital blood bank of the University of Bari. SLE patients
were used as a control group, because in both SSc and
SLE the T helper 2 (Th2) immune response appears to
play an important role in mediating the autoimmune
damage [29,30]. Sera were stored at -80°C until use.
Electrophoresis reagents were purchased from Bio-Rad
Laboratories (Segrate, Italy). Polyclonal human IgG pre-
parations for intravenous use (IVIG, Intratec®, Dreieich,
Germany) were purchased from Biotest (Dreieich, Ger-
many). Horseradish-peroxidase (HRP)-conjugated xeno-
Ab to human IgG (Fc portion) was purchased from Jack-
son Immunoresearch Laboratories (Avondale, PA, USA).
Unless otherwise specified, all other chemicals were pur-
chased from BDH Merck (Poole, Dorset, UK) or Sigma-
Aldrich (St Louis, MO, USA). Peptides were synthesized
by Primm (Milan, Italy). Their purity, determined by ana-
lytical reverse phase chromatography and mass spectro-
metry, ranged between 91.3% and 100%. Peptides were
coupled to BSA by means of glutaraldehyde, as previously
described [31].
Serological assays (indirect ELISA)
The reactivity and specificity of Ab with peptide were
assessed by indirect ELISA, as described [32], with minor
modifications. Briefly, U-bottom 96-well polyvinylchloride
plates (BD Falcon, Franklin Lakes, NJ, USA) were incu-
bated with 50 µl PBS containing 5 µg/ml BSA-conjugated
peptide, for 12 h at 4°C. Wells were washed once with PBS
containing 0.05% Tween 20 (PBS-T20) and blocked with
PBS containing 0.5% BSA (PBS-BSA). Serum samples
(diluted 100 times in PBS-BSA) were added to the wells
and incubated for 4 h at 25°C. Wells were washed three
times with PBS-T20. Bound IgG was detected by sequen-
tial incubation with HRP-conjugated xeno-Ab to the Fc
portion of human IgG (1 h at 25°C) and o-phenylenedia-
mine (0.5 mg/ml; 100 µl/well); color development was
stopped by adding 100 µl 2 N H2SO4 and the absorbance
was read at 490 nm with the Benchmark microplate reader
(Bio-Rad Laboratories). Background binding was deter-
mined from the absorbance generated in wells with
blocking solution alone. Specific binding was determined
by subtracting the background absorbance from the absor-
bance in experimental wells. Samples with the highest
binding for each peptide were selected for affinity purifica-
tion of the corresponding Ab.
Affinity purification of human autoantibodies
CENP-A-derived peptides Ap1-17 (1MGPRRRSRKP-
EAPRRRS17) and Ap17-30 (17SPSPTPTPGPSRRG30)
and FOXE3-derived peptide FOXE3p53-62 (53PTPAPG-
PGRR62) were conjugated to Affi-Gel 15 (Bio-Rad
Laboratories) at a concentration of 2 mg/ml resin fol-
lowing the manufacturer’s instructions; these conjugated
resins were used to affinity-purify the corresponding
anti-peptide Ab as previously described [18], from a
pool of a few serum samples with the highest binding
avidity. Briefly, 5 ml pooled serum was diluted in an equal
volume of PBS and repeatedly passed through a BSA-con-
jugated Affi-Gel 15 column, and then absorbed several
times on a peptide-conjugated Affi-Gel 15 column. Bound
IgG was eluted, dialyzed overnight against PBS and con-
centrated by lyophilization. Ab concentration was deter-
mined by UV absorption with a 1.35 extinction coefficient
at 280 nm for 1 mg/ml protein. The extent of contamina-
tion of samples by human serum albumin was assessed by
SDS-PAGE, Coomassie brilliant blue staining, and density
scanning; the final concentration of IgG was corrected to
reflect this contamination. The specificity of purified Ab
for peptides was assessed as previously described [18].
ELISA quantification of autoantibody levels in sera
Serum levels of anti-Ap1-17, anti-Ap17-30 and anti-
FOXE3p53-62 IgG were measured by ELISA as pre-
viously described [32]. Briefly, 96-well polyvinylchloride
plates were coated with 50 µl PBS containing 5 µg/ml
BSA-conjugated peptide, for 12 h at 4°C. Wells incu-
bated with BSA alone were used as negative controls.
Wells were washed once with PBS-T20 and blocked with
PBS-BSA. Standard (calibration) curves were generated by
incubating the wells with known concentrations of affi-
nity-purified anti-peptide Ab up to a maximum 2.5 µg/ml.
To quantify the concentration of anti-peptide Ab in serum
samples, 50 µl of 4-fold serial dilutions of sera (starting
dilution 1:40) was added to the wells. After 4 h, wells were
washed three times with PBS-T20. The assay was then
continued as described above (Serological assays). Peptide-
specific IgG concentration (µg/ml) was determined from
the calibration curve and corrected for the dilution factor.
Statistical analyses
Receiver operating characteristics (ROC) analysis was
used to find cutoff points for dichotomizing continuous
variables [33]. This analysis was performed using Med-
Calc software (v. 7.6.0.0) (MedCalc Software bvba,
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Ostend, Belgium), and the discriminating cutoff was
automatically obtained. The Mann-Whitney test was
used with continuous variables for comparisons between
groups, the chi-squared and Fisher exact tests were used
to define associations among dichotomized variables, and
multivariate analysis was used to define independent
associations between two variables; these statistical tests
were performed using SPSS v. 20 for Windows. A
P-value <0.05 indicated statistical significance.
Results
The 75 ACA+ and 46 ACA- patients (Table 1) were simi-
lar in sex distribution, age at diagnosis and disease dura-
tion. ACA+ patients were more likely to have the limited
subtype of SSc (93.3% versus 52.2%; P < 0.0001), and as a
group had lower mRss values for skin involvement (mean
3.9 versus 9.0; P <0.0001). Despite similar values of sPAP
and rates of PAH, the ACA+ group had a lower frequency
of ILD (18.0% versus 78.6%; P < 0.0001) and higher per-
centages of predicted FVC and DLCO. Their overall dis-
ease severity score was also lower (mean 5.17 versus 7.20;
P = 0.009) and this was reflected in significant differences
between groups in the two domains of skin and joint/ten-
don involvement. No significant difference was observed
for disease activity index.
The study included two additional control groups: 46
patients with SLE and 25 HBD. The mean (± SD) age at
diagnosis of the SSc patients (38.8 ± 14.3) was similar to
that of the SLE patients (34.5 ± 9.6) and HBD (34.5 ±
4.6). As expected, among both SSc and SLE patients, the
female sex predominated (94.7% and 91.3%, respec-
tively), but there was a more balanced sex distribution
among HBD (56% female). All patients and HBD were
self-declared white Caucasians.
Levels of anti-Ap1-17, anti-Ap17-30 and anti-FOXE3p53-
62 Ab in patients’ sera
To quantify anti-peptide Ab in the patients’ sera, we first
purified these antibodies from samples with the highest
binding avidity to generate standard curves in indirect
ELISA. Based on an initial ELISA screening of the 75 ACA
+ sera with Ap1-17, Ap17-30 and FOXE3p53-62 peptides,
sera from three, four and three patients, respectively, were
pooled and used in affinity chromatography; this resulted
in the purification of anti-Ap1-17 and anti-Ap17-30 Ab,
but not anti-FOXE3p53-62 Ab. The calibration curves for
anti-Ap1-17 and anti-Ap17-30 Ab permitted detection in
the range of 0.28 to 6037 µg/ml, and 0.08 to 32.85 µg/ml,
respectively. Because attempts to purify Ab from a
FOXE3p53-62-conjugated column were unsuccessful, the
Table 1 Clinical characteristics of 121 patients with systemic sclerosis (SSc) according to the presence or absence of
anti-centromere-associated protein antibodies (ACA)
Variable All patients ACA-positive (n = 75) ACA-negative (n = 46) P-value
Female, n (%) 113 (93.4) 71 (94.7) 42 (91.3) 0.470a
Age at diagnosis, years 38.8 (14.3) 39.3 (13.7) 37.8 (15.5) 0.530b
Disease duration, years 17.1 (10.3) 18.4 (10.6) 14.7 (9.4) 0.050b
Limited disease, n (%) 94 (77.7) 70 (93.3) 24 (52.2) <0.0001 a
mRss 5.70 (7.00) 3.90 (6.40) 9.00 (7.10) <0.0001 b
FVC, % of predicted 105.60 (20.20) 107.40 (19.10) 84.30 (22.20) 0.014b
DLCO, % of predicted 73.10 (23.80) 76.60 (25.00) 64.10 (17.80) 0.017b
sPAP, mm Hg 28.10 (10.60) 27.70 (11.60) 28.80 (8.80) 0.058b
ILD, n (%) 24 (27.6) 13 (18.0) 36 (78.6) <0.0001a
PAH, n (%) 16 (13.2) 8 (10.7) 8 (17.4) 0.289a
Disease severity scale
Total score 5.89 (3.46) 5.17 (2.80) 7.20 (4.12) 0.009b
General 0.50 (0.80) 0.44 (0.70) 0.60 (0.93) 0.484b
Peripheral vascular 1.52 (0.71) 1.46 (0.68) 1.61 (0.76) 0.212b
Skin 0.83 (0.65) 0.66 (0.64) 1.14 (0.56) <0.0001b
Joint/tendon 0.47 (1.00) 0.26 (0.64) 0.85 (1.35) 0.012b
Muscle 0.16 (0.50) 0.10 (0.42) 0.26 (0.62) 0.090b
Gastrointestinal tract 0.83 (0.70) 0.77 (0.66) 0.94 (0.72) 0.200b
Lung 1.34 (1.11) 1.22 (1.18) 1.54 (0.96) 0.111b
Heart 0.24 (0.50) 0.24 (0.42) 0.25 (0.63) 0.514b
Kidney 0.05 (0.41) 0.0 (0.0) 0.14 (0.68) 0.058b
Disease activity index 1.52 (1.68) 1.26 (1.31) 1.98 (2.14) 0.128b
Values are presented as mean (SD) unless otherwise indicated. aChi-squared test; bMann-Whitney U-test. mRss, modified Rodnan skin score; FVC, forced vital
capacity; DLCO, diffusing lung capacity for carbon monoxide; sPAP, systolic pulmonary arterial pressure; PAH, pulmonary arterial hypertension (sPAP >35 mm Hg);
ILD, interstitial lung disease.
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calibration curve to measure these serum levels was con-
structed using anti-Ap17-30-specific IgG purified from a
pool of the three additional SSc serum samples displaying
the highest binding to FOXE3p53-62. The range of detec-
tion of this assay was 1.32 to 880 µg/ml.
The levels of anti-Ap1-17, -Ap17-30 and -FOXE3p53-62
IgG in sera of 75 ACA+ SSc patients, 46 ACA- SSc
patients, 46 SLE patients and 25 HBD are illustrated in
Figure 1. As expected, the levels of anti-Ap1-17 and
-Ap17-30 IgG in ACA+ SSc patients were markedly higher
than in the other groups (Mann-Whitney, P < 0.0001); the
mean levels of these Ab in the other groups were at least
10-fold lower and not significantly different among groups.
Anti-FOXE3p53-62 Ab were again highest in the ACA+
SSc group (P < 0.0001 versus ACA- SSC; P = 0.001 versus
SLE patients; P <0.0001 versus HBD). These data suggest
that anti-FOXE353-62 reactivity is more pronounced in
ACA+ SSc patients.
Dichotomization of anti-peptide Ab levels in relation to
the presence or absence of ACA
As a first step to identifying clinical correlates of anti-
FOXE353-62 Ab, we used ROC analysis to define cutoff
concentrations of the three anti-peptide Ab that could
discriminate between ACA+ and ACA- patients. When
the analysis was performed for anti-FOXE3p53-62 IgG,
the concentration that best discriminated the ACA+ and
ACA- groups was 74.5 µg/ml (sensitivity, 53%; specificity,
90%; area under the curve (AUC), 0.70) (Figure 2A). If
instead of the ACA- group we used HBD as the control,
we obtained the same cutoff and sensitivity (Figure 2D)
and slightly higher specificity (96%) and AUC (0.77).
When ROC analysis was performed for anti-Ap1-17 IgG
using both ACA- (Figure 2,B) and HBD (Figure 2E) as the
comparison groups, the sensitivity (88% and 93%, respec-
tively), specificity (98% and 88%) and AUC (0.96 and 0.95)
were markedly higher, as expected by the fact that Ap1-17
and Ap17-30 are CENP-A-derived peptides. Similar results
were obtained for anti-Ap17-30 IgG, with sensitivity (83%
and 92%, respectively), specificity (100% and 96%) and
AUC (0.94 and 0.97) versus ACA- (Figure 2C) and HBD
(Figure 2F).
Using the three cutoffs for ACA+ versus ACA-, we
dichotomized serum levels of anti-Ap1-17, -Ap17-30 and
-FOXE3p53-62 Ab as positive (above the cutoff) or nega-
tive (below the cutoff). Among ACA+ SSc patients, three
were negative for all three Ab, thirty-five were positive for
all three Ab, and thirty-seven were positive for one or two
of the Ab (the most common combination was anti-Ap1-
17 and anti-Ap17-30 in twenty-one patients). Comparing
Figure 1 Levels (mean, range) of antibodies to anti-Ap1-17 (panel A), -Ap17-30 (panel B) and anti-FOXE3p53-62 (panel C) in patients
with systemic sclerosis (anticentromere antibody-positive and -negative) and systemic lupus erythematosus, and in healthy blood
donors. Ab levels were measured by enzyme-linked immunosorbent assay (ELISA), using appropriate standard curves. The proportion of the
difference of the levels between groups was evaluated by the Mann-Whitney U-test. P <0.05 was considered significant. Ab, autoantibodies; ACA+,
anticentromere antibody-positive; ACA-, anticentromere antibody-negative; SLE, systemic lupus erythematosus; HBD, healthy blood donors.
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across groups (Table 2), anti-Ap1-17 Ab and anti-Ap17-30
Ab were scored as being positive in 66 and 62 ACA+ SSc
patients (88.0% and 82.6%, respectively), whereas low fre-
quencies were observed in the other groups. Anti-
FOXE3p53-62 Ab were scored positive in 40 ACA+ SSc
patients (53.3%) and in 13 (28.3%) SLE patients. Looking
further at the concomitant expression of the different Ab,
all 40 ACA+ SSc patients who were positive for anti-
FOXE3p53-62 Ab were also positive for anti-Ap1-17 Ab
or anti-Ap17-30 Ab (or both). In contrast, only three
(23.1%) of the thirteen SLE patients who were positive for
anti-FOXE3p53-62 Ab were positive for at least one of the
other Ab. These data suggest that the expression of Ab to
FOXE3p53-62 and to Ap1-17 or Ap17-30 may be asso-
ciated in SSc but not in SLE.
Clinical correlates of anti-FOXE3p53-62 Ab
To identify possible clinical correlates of anti-FOXE3p53-
62 Ab, the ACA+ SSc patients were divided into subgroups
according to whether they scored positive (n = 40) or
negative (n = 35) (Table 3). The subgroups were similar
for most clinical and laboratory variables, including the
levels of anti-Ap1-17 Ab. There were significant differ-
ences, however, in the levels of anti-Ap17-30 Ab, which
were higher in the FOXE3p53-62-positive group (Mann-
Whitney P <0.0001), and in the disease activity index,
which was higher (more active disease) in the FOXE3p53-
62-negative group (Mann-Whitney P = 0.038). The differ-
ence in the disease activity index was explained by higher
scores in two particular domains, namely deterioration in
heart/lung function and hypocomplementemia.
This clinical association was explored further by looking
at the numbers of ACA+ patients with active disease
(defined as a disease activity index ≥2.5 or ≥3.0) and by
analyzing the disease activity data as frequencies of patients
with particular symptoms in each domain (Figure 3). The
FOXE3p53-62-negative group had higher percentages of
patients with active disease when defined both with a cutoff
of 3.0 (Fisher exact test, P = 0.045) and a less restrictive cri-
terion of 2.5 (P = 0.009). For the individual index items, the
FOXE3p53-62-negative group had higher percentages of
patients with deterioration in heart/lung function and
Figure 2 Receiver operating characteristic analysis to define the best cutoffs of anti-peptide (Ap1-17, Ap17-30 and FOXE3p53-62)
autoantibody levels discriminating anticentromere antibody-positive from and anticentromere antibody-negative patients (panels A
to C), or from healthy blood donors (panels D to F). Ab, autoantibodies.
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hypocomplementemia; no other significant differences
between groups were detected for the remaining items
(data not shown).
Finally, multivariate regression was performed to
detect any independent associations between the levels
of anti-FOXE3p53-62 Ab in ACA+ SSc patients and
clinical variables and to identify any possible confound-
ing factors such as age, disease duration and ANA titer
(Table 4). The level of anti-Ap17-30 Ab and disease
activity index were retained in the model as the only
independent variables. Disease activity index displayed
an inverse association with anti-FOXE3p53-62 Ab levels:
positivity for anti-FOXE3p53-62 Ab was associated with
low scores of the disease activity index after statistical
correction for multiple comparisons (P = 0.035). When
multivariate regression analysis was performed including
Table 2 Presence of anti-peptide IgG in sera from patients with SSc or SLE and healthy blood donors, according to the
best cutoffs for discriminating ACA-positive from ACA-negative SSc patients





Ap1-17+ >10.4 66 (88.0) 1 (2.2) 2 (4.3) 3 (12.0)
Ap17-30+ >1.2 62 (82.6) 2 (4.3) 4 (8.7) 1 (4.0)
FOXE3p53-62+ >74.5 40 (53.3) 5 (10.9) 13 (28.3) 1 (4.0)
FOXE3p53-62+ and Ap1-17+ or Ap17-30+ 40 (100)b 0 (0) b 3 (23.1) b 1 (100) b
Values are presented as n (%) from a sample of 121 patients with SSc, 46 patients with SLE, and 25 HBD. aCutoffs were defined using receiver operating
characteristic analysis; bpercentage of FOXE3p53-62+ samples that were also positive for Ap1-17 and/or Ap17-30. ACA, anti-centromere-associated protein
antibodies; SSc, systemic sclerosis; SLE, systemic lupus erythematosus; HBD, healthy blood donors.
Table 3 Clinical characteristics of 75 ACA+ (>74
Variable Anti-FOXE3p53-62 P-value
Positive (n = 40) Negative (n = 35)
Female, n (%) 38 (95.0) 33 (94.3) 1.000a
Age at diagnosis, years 37.4 (14.2) 41.5 (13.0) 0.217b
Disease duration, years 20.3 (11.9) 16.2 (8.5) 0.151b
Disease subtype, limited, n (%) 37 (92.5) 33 (94.3) 0.757a
Anti-Ap1-17 IgG, µg/ml 252.50 (954.00) 161.00 (313.00) 0.807b
Anti-Ap17-30 IgG, µg/ml 9.63 (7.00) 5.23 (7.20) <0.0001b
mRss 3.70 (4.20) 4.10 (8.40) 0.533b
FVC, % of predicted 110.6 (17.0) 103.7 (20.6) 0.201b
DLCO, % of predicted 76.2 (24.0) 76.6 (24.6) 0.727b
sPAP, mm Hg 29.00 (14.20) 26.20 (8.20) 0.510b
ILD, n (%) 8 (20.0) 5 (15.2) 0.590 a
PAH, n (%) 5 (12.5) 3 (8.6) 0.719a
Disease severity score 5.30 (2.70) 5.00 (2.30) 0.570b
Disease activity index 0.91 (0.91) 1.61 (1.61) 0.038b
Disease activity index domains
mRss >14 (0.0, 1.0) 0.02 (0.16) 0.03 (0.17) 0.980
Scleredema (0.0, 0.5) 0.11 (0.21) 0.11 (0.21) 0.971
Skin (0.0, 2.0) 0.05 (0.30) 0.10 (0.50) 0.481
Digital necrosis (0.0, 0.5) 0.07 (0.18) 0.04 (0.14) 0.396
Vascular (0.0, 0.5) 0.06 (0.16) 0.06 (0.16) 0.887
Arthritis (0.0, 0.5) 0.07 (0.20) 0.06 (0.16) 0.652
DLCO <80% of predicted (0.0, 0.5) 0.26 (0.25) 0.20 (0.25) 0.282
Heart/lung function (0.0, 2.0) 0.05 (0.31) 0.40 (0.81) 0.015
ESR >30 mm/h (0.0, 1.5) 0.18 (0.50) 0.30 (0.60) 0.380
Low C3 or C4 (0.0, 1.0) 0.05 (0.22) 0.31 (0.50) 0.003
Values are presented as mean (SD) unless otherwise indicated. aChi-squared test; bMann-Whitney U-test; a P-value <0.05 was considered significant. SSc, systemic
sclerosis; ACA, anti-centromere-associated protein antibodies; mRss, modified Rodnan skin score; FVC, forced vital capacity; DLCO, diffusing lung capacity for
carbon monoxide; sPAP, systolic pulmonary arterial pressure; ILD, interstitial lung disease assessed by high resolution computed tomography; PAH, pulmonary
arterial hypertension (sPAP >35 mm Hg); ESR, erythrocyte sedimentation rate in the first hour. Cardiac involvement was evaluated by electrocardiography,
echocardiography and physical examination.
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complement as a dichotomized variable, complement
(B = -2.42; Exp(B) = 0.089; P = 0.030) and anti-Ap17-30
Ab level (B = 0.115; Exp(B) = 1.12; P = 0.028) were
retained as the only independent variables. Altogether,
these data indicate that ACA+ SSc patients with high
anti-FOXE3p53-62 Ab levels are significantly less sus-
ceptible to developing active disease than ACA+ SSc
patients with low levels of these Ab.
Discussion
In a previous study, we defined the fine specificity of anti-
CENP-A Ab and discovered that one of the two identified
binding motifs was present not only in CENP-A but also
in FOXE3, a protein not previously implicated in SSc [18].
As a first step to understanding if anti-FOXE3 Ab are of
clinical interest, we measured their levels in patients with
SSc and SLE and in HBD and searched for clinical corre-
lates. This work revealed that SSc patients who are posi-
tive for anti-FOXE3p53-62 Ab are less likely to have active
disease than SSc patients who have ACA but are negative
for anti-FOXE3p53-62.
SSc patients who tested positive for ACA on standard
laboratory tests were frequently found to have Ab reactiv-
ity to CENP-A peptides: 88.0% and 82.2% of sera from
ACA+ SSc patients reacted with Ap1-17 and Ap17-30,
respectively. This finding parallels a similar observation by
Akbarali et al. [19], who found that 80% of ACA+ sera
reacted with the CENP-A peptide spanning amino acids
Figure 3 Frequency of active disease in anticentromere antibody-positive systemic sclerosis patients, according to the positivity/negativity
of anti-FOXE3p53-62 autoantibodies. Patients were divided into anti-FOXE3p53-62-positive and -negative groups according to the cutoff (>74.5
µg/ml) that best discriminated anticentromere antibody (ACA)-positive from ACA-negative patients with systemic sclerosis. Active disease was
defined as a disease activity index (DAI) ≥3.0 or ≥2.5. Patients were scored as being positive or negative for the 10 items of the DAI. Differences
between groups were assessed using Fisher’s exact text. No significant differences were observed in the remaining eight items of the DAI.
Table 4 Logistic multivariate regression to detect
independent associations between anti-FOXE3p53-62 Ab
levels and clinical and laboratory parameters (continuous
and dichotomized) in 75 ACA+ patients
Variable B coefficient Exp (B) P-valuea 95% CI
Gender -0.065 1.067 0.956 0.104, 0.914
Age at diagnosis -0.022 0.978 0.465 0.922, 1.038
Disease duration 0.039 1.040 0.661 0.943, 1.096
mRss -0.06 0.942 0.277 0.846, 1.049
ESR 0.004 1.004 0.847 0.962, 1.049
CRP -0.052 0.949 0.749 0.689, 1.307
ANA titer 0.000 1.000 0.550 0.999, 1.002
Anti-Ap1-17 IgG 0.00 1.000 0.678 0.999, 1.001
Anti-Ap17-30 IgG 0.108 1.114 0.035 1.007, 1.231
Disease severity score 0.138 1.148 0.315 0.977, 1.501
Disease activity index -0.711 0.491 0.035 0.254, 0.950
aA P-value >0.05 was not considered statistically significant. ACA, anti-
centromere-associated protein antibodies; ANA, anti-nuclear antibodies; CRP,
C-reactive protein; ESR, erythrocyte sedimentation rate; mRss, modified
Rodnan skin score.
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17 to 30. It is likely that the higher percentage of reactivity
recorded in the present study reflects the different metho-
dology employed, because Akbarali et al. used peptide-
coated pins, whereas we used BSA-conjugated peptide
adsorbed onto microtiter plate wells. These findings,
together with the high specificity and sensitivity deter-
mined by ROC analysis, suggest that Ap17-30 and Ap1-17
peptides can be used as antigens in ELISAs just as effec-
tively as recombinant CENPs currently used in commer-
cial ACA assays.
The frequencies of different disease manifestations in
ACA+ and ACA- SSc patients are similar, though not
identical to those reported in a recent study by Hanke
et al. [34]. In both studies, skin involvement and ILD
was more frequent in the ACA- group. At variance from
Hank et al., however, we found no significant differences
regarding cardiac involvement. The discrepancy in the
results may reflect the different percentages of ACA-
patients with limited disease recorded in two studies,
which was 18.4 % in the cohort of Hanke et al., whereas
it was 52.2% in our study.
The apparent discrepancy between heart/lung function
(significantly different between anti-FOXE3p53-62-positive
and -negative groups) on one hand, and FVC, DLCO,
sPAP, ILD and PAH (equally distributed between groups)
on the other, is likely to reflect the differences in the signif-
icance of heart/lung function compared to the other func-
tions. In fact, while the former is based on the patients’
self-assessments of the deterioration of cardiopulmonary
manifestations (mainly based on the severity of effort dys-
pnea, which occurred in the previous month), FVC,
DLCO, sPAP, ILD and PAH record the degree of func-
tional deterioration that cannot be strictly correlated to
symptoms. Supporting this possibility was the lack of any
significant association (chi-squared test) between the heart/
lung item of the disease activity index and FVC (<80%),
DLCO (<80%) or sPAH (>35 mm Hg) (data not shown).
The biological significance of ACA reactivity with
FOXE3p53-62 deserves some comments. One can argue
that due to the homology of FOXE3p53-62 and CENP-A-
derived Ap17-30 (80% identical, 10% strongly similar) [18],
anti-FOXE3p53-62 Ab are simply CENP-A17-30-specific
Ab that cross-react with FOXE3p53-62. Though this pos-
sibility cannot be ruled out in ACA+ patients, considering
the positive association between levels of anti-FOXE3p53-
62 and anti-Ap17-30 Ab, two lines of evidence suggest
that anti-FOXE3p53-62 Ab can be generated indepen-
dently of anti-Ap17-30. First, 46.7% of sera from the ACA
+ group reacted with Ap17-30 peptide only, indicating that
in certain patients, anti-CENP-A Ab do not necessarily
cross-react with FOXE3p53-62. Second, sera from two
ACA- SSc patients and ten SLE patients reacted with
FOXE3p53-62 only. Although the significance of the pre-
sence of FOXE3p53-62-specific Ab in SLE is unknown, it
is clear that under certain conditions the expression of
anti-FOXE3p53-62 Ab is dissociated from that of anti-
CENP-A Ab.
A significantly lower disease activity index was
recorded in the subset of ACA+ SSc patients who were
FOXE3p53-62-positive. Although this subgroup was
relatively small, as were the numbers of patients with
active disease, this finding was confirmed by reanalysis
using the Fisher test and by multivariate analysis, which
excluded any influence of potential confounding factors
(patient’s age, disease duration, ANA titer, or ESR).
Multivariate analysis also highlighted the independent
associations between active disease and low levels of
anti-FOXE3p53-62 Ab and indicated that a low comple-
ment-domain of the disease activity index plays a major
role in the association.
The clinical correlation of disease severity scores and
auto-Ab has been extensively reported in SSc (reviewed
in [16,35,36]). Examples include a higher incidence of:
1) lung involvement in anti-topo-I- [37,38] and anti-
Ro52/TRIM21-positive patients [39]; 2) renal crisis and
poorer prognosis in anti-RNA polymerase (RNAP)I/III-
positive patients [40,41]; 3) PAH in patients with anti-
vascular smooth muscle cell Ab [42] or in ACA+
patients [15,37,43], and 4) digital ulceration and muscu-
lar involvement in anti-PM/Scl-75/100-positive patients
[44] and in anti-U3RNP Ab-positive patients [45]. Even
so, none of these investigations have shown any correla-
tion between SSc auto-Ab and disease activity. To the
best of our knowledge, this is the first report to describe
the ability of auto-Ab to discriminate a subset of ACA+
patients, namely those who are less likely to have active
disease.
It is not clear whether high levels of anti-FOXE3p53-
62 Ab protect patients from developing active disease
or, on the contrary, whether the lack of an active disease
state promotes the generation of anti-FOXE3p53-62 Ab.
We favor the first possibility, as preliminary results on
serial samples of six patients collected over a period of
2 years suggest that the levels of these Ab remain con-
stant. Moreover, as this was a two-center study, addi-
tional studies are needed to validate our findings in
patients being cared for at multiple institutions.
Conclusions
The measurement of anti-FOXE3p53-62 Ab levels adds
specific clinical information beyond that provided by
ACA measurements, by defining a subgroup of SSc
patients (FOXE3p53-62-positive) who are less likely to
develop active disease. Future follow-up studies will
evaluate how the presence of these Ab influences the
prognosis of these patients.
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